USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Advanced Therapeutics for the Infectious Disease Management Market, Global, 2024-2029
The emergence of novel pathogens and the reemergence of old pathogens are driving transformational growth by pushing therapeutic advancement.
16-Jan-2025
Global
Technology Research
Antimicrobial resistance (AMR), the emergence of new pathogens, and breakthroughs in biotechnology have significantly transformed the global landscape of infectious diseases. This Frost & Sullivan report focuses on advanced therapeutics for the infectious disease management industry. It offers an analysis of clinical trials for 3 treatment modalities, specifically RNA therapeutics, antibody-based medicines, and bacteriophage therapies, and highlights key innovators in each area. The study identifies the factors driving growth, including the rising incidence of resistant infections, advancements in precision medicine technologies, and supportive regulatory environments. It also discusses challenges such as high development costs, complex production requirements, and regulatory hurdles, providing a comprehensive view of market dynamics. The report outlines potential growth opportunities for companies, such as affordable antibody therapeutics, collaborations in phage therapy with academic institutions and biotech firms, and exploration of RNA therapeutics beyond mRNA. Additionally, it identifies significant innovators, their strategic partnerships, and current funding trends that indicate an increasing investment in this area. This comprehensive research provides stakeholders valuable insights to navigate the infectious disease treatment market, capitalize on emerging opportunities, and foster innovation to tackle global health challenges.
Questions Addressed in This Report:
• What are the key drivers and constraints in the advanced therapeutics for infectious disease management space?
• What clinical trends are emerging across each therapeutic approach for managing infectious diseases?
• Who are the main industry players developing innovative therapeutics for infectious disease management?
• What does the funding and partnership landscape look like in the advanced therapeutics for the infectious disease management industry?
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Advanced Therapeutics for the Infectious Disease Management Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Introduction
Scope of Analysis
Segmentation
Growth Drivers
Growth Restraints
Clinical Trial Analysis of RNA–based Therapeutics
Clinical Trial Analysis of RNA–based Therapeutics (continued)
Key Innovators: RNA-based Therapeutics for Infectious Diseases
Key Innovators—RNA–based Therapeutics for Infectious Diseases (continued)
Clinical Trial Analysis of Antibody Therapeutics
Antibody Therapy
Key Innovators: Antibody-based Therapeutic Approach for Infectious Diseases
Clinical Trial Analysis of Phage Therapy
Key Innovators: Phage-based Therapeutic Approach for Infectious Diseases
Recent Funding for Infectious Disease Management
Partnership Landscape in Infectious Disease Management
Growth Opportunity 1: Targeted and Precision Antibody Therapeutics
Growth Opportunity 1: Targeted and Precision Antibody Therapeutics (continued)
Growth Opportunity 2: RNA Therapeutics Beyond mRNA
Growth Opportunity 2: RNA Therapeutics Beyond mRNA
Growth Opportunity 3: Phage Therapy
Growth Opportunity 3: Phage Therapy
Benefits and Impacts of Growth Opportunities
Next Steps
Legal Disclaimer
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Technology Research |
|---|---|
| Author | Priyanka Jain |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Podcast | No |
| WIP Number | DB12-01-00-00-00 |